Evidence map›Paper›PMID 42808115›Full record

ArticleACG case reports journal2026

Dual-Targeted Therapy With Upadacitinib and Ustekinumab in Pediatric Refractory Perianal Crohn's Disease.

Neha Sathe, Meredith Kline, Amelia Kellar, David Choi, Ranjana Gokhale

Abstract readCase Reports
In one paragraph

Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Neha SatheDepartment of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.ORCID https://orcid.org/0009-0008-9826-4990
Meredith KlineDepartment of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
Amelia KellarDepartment of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
David ChoiDepartment of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
Ranjana GokhaleDepartment of Medicine, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Perianal Crohn's disease (pCD) is a challenging manifestation of CD. We present the case of a 17-year-old adolescent girl with severe, refractory pCD, complicated by a rectovaginal fistula, who failed multiple lines of therapy and required a temporary ileostomy. While on upadacitinib (UPA) monotherapy, she experienced a flare with magnetic resonance imaging (MRI)-confirmed perianal abscesses. The addition of ustekinumab (UST) to UPA resulted in marked improvement in clinical symptoms and radiographic resolution of perianal disease on follow-up MRI. No adverse events occurred. This case highlights dual UPA/UST therapy as a promising strategy for severe, refractory pCD in an adolescent.

Indexed as

dual therapypediatric inflammatory bowel diseaseperianal Crohn's diseaseupadacitinibustekinumab

Identifiers

PMID42808115
PMCPMC13619283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.